<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03604861</url>
  </required_header>
  <id_info>
    <org_study_id>INDV-6000-N01</org_study_id>
    <nct_id>NCT03604861</nct_id>
  </id_info>
  <brief_title>An Observational Study of Environmental and SocioEconomic Factors in Opioid Recovery</brief_title>
  <acronym>RECOVER®</acronym>
  <official_title>Remission From Chronic Opioid Use: Studying Environmental and SocioEconomic Factors on Recovery—The RECOVER Study®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indivior Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indivior Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The RECOVER Study will examine clinical, environmental and socioeconomic factors in recovery
      from opioid use disorder (OUD) over a 24-month period following exit from a Phase III
      clinical program for a buprenorphine extended-release injection (RBP-6000). The study
      population will consist of participants from studies NCT02357901 (RB-US-13-0001) and
      NCT02510014 (RB-US-13-0003).

      The RECOVER study will characterize OUD subjects' recovery process as they transition from
      the controlled clinical trial environment to the real world setting.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Actual">March 2019</completion_date>
  <primary_completion_date type="Actual">March 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Reported Abstinent From Opioids For the Previous 7 Days and Previous 28 Days at Month 24</measure>
    <time_frame>Month 24</time_frame>
    <description>Based on self-reported abstinence from opioids using the National Survey on Drug Use and Health (NSDUH).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Percentage of Participants Who Reported Abstinent From Opioids For the Previous 7 Days At Months 3, 6, 9, 12, 15, 18, 21, 24</measure>
    <time_frame>Baseline (Day 1), Months 3, 6, 9, 12, 15, 18, 21, 24</time_frame>
    <description>Based on self-reported abstinence from opioids using the National Survey on Drug Use and Health (NSDUH).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Percentage of Participants Who Reported Abstinent From Opioids For the Previous 28 Days At Months 3, 6, 9, 12, 15, 18, 21, 24</measure>
    <time_frame>Baseline (Day 1), Months 3, 6, 9, 12, 15, 18, 21, 24</time_frame>
    <description>Based on self-reported abstinence from opioids using the National Survey on Drug Use and Health (NSDUH).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Reported Abstinent From Opioids For the Previous 7 Days and Confirmed by Urine Drug Screen (UDS) at Month 24</measure>
    <time_frame>Month 24</time_frame>
    <description>Based on self-reported abstinence from opioids (using NSDUH), and confirmed by UDS.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Percentage of Participants Who Reported Abstinent From Opioids For the Previous 7 Days and Confirmed by UDS At Months 3, 6, 9, 12, 15, 18, 21, 24</measure>
    <time_frame>Baseline (Day 1), Months 3, 6, 9, 12, 15, 18, 21, 24</time_frame>
    <description>Based on self-reported abstinence from opioids (using NSDUH), and confirmed by UDS.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Change from Baseline in 12-Item Short Form Health Survey, Version 2 (SF-12v2) to Months 12 and 24</measure>
    <time_frame>Baseline (Day 1), Months 12 and 24</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline in the Subjective Opioid Withdrawal Scale (SOWS) to Months 12 and 24</measure>
    <time_frame>Baseline (Day 1), Months 12 and 24</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline in the Beck Depression Inventory (BDI) to Months 12 and 24</measure>
    <time_frame>Baseline (Day 1), Months 12 and 24</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline in the Brief Pain Inventory (BPI) to Months 12 and 24</measure>
    <time_frame>Baseline (Day 1), Months 12 and 24</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants Currently Employed at Baseline, Month 12 and Month 24</measure>
    <time_frame>Baseline (Day 1), Months 12 and 24</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Amount of Health Care Resource Utilization (HCRU) at Months 1-12 and Months 13-24</measure>
    <time_frame>Months 1-12 and Months 13-24</time_frame>
    <description>HCRU information includes hospitalizations, residential substance abuse treatment, general practitioner/specialist/and counseling visits, and emergency department (ED) visits.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Crimes Committed at Baseline, Months 1-12 and Months 13-24</measure>
    <time_frame>Baseline (Months -6 to Day 1), Months 1-12 and Months 13-24</time_frame>
    <description>Participants complete surveys to identify the number and type of criminal incidents in a given time frame. These questions include information on arrests, violence, unlawful behaviors, and driver's license status.</description>
  </other_outcome>
  <enrollment type="Actual">534</enrollment>
  <condition>Opioid-use Disorder</condition>
  <condition>Opioid-related Disorders</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Not applicable - no defined intervention</intervention_name>
    <description>Participants who received at least one injection of RBP-6000 or placebo and either withdrew from or completed the Phase III clinical program which included studies NCT02357901 (RB-US-13-0001) and NCT02510014 (RB-US-13-0003) were eligible for the RECOVER Study.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are currently diagnosed with moderate or severe OUD according to Diagnostic
        and Statistical Manual 5 (DSM-5) criteria and for 3 months immediately prior to signing the
        informed consent form for protocols NCT02357901 (RB-US-13-0001) and/or NCT02510014
        (RB-US-13-0003).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who received at least one injection in RBP-6000 or placebo in the Phase III
             clinical program which includes study protocols NCT02357901 (RB-US-13-0001) and
             NCT02510014 (RB-US-13-0003) and either withdrew from or completed these studies.

          -  Ability to comply with study protocol requirements for data collection and provide
             informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director, Global Medicines Development</last_name>
    <role>Study Chair</role>
    <affiliation>Indivior Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Winston Technology Research LLC</name>
      <address>
        <city>Haleyville</city>
        <state>Alabama</state>
        <zip>35565</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boyett Health Services</name>
      <address>
        <city>Hamilton</city>
        <state>Alabama</state>
        <zip>35570</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Woodland International Research Group</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Behavioral Research Specialists</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Networks, Inc.</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synergy Research Center</name>
      <address>
        <city>National City</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North County Clinical Research</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amit Vijapura</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Try Research</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Clinical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific Clinical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Centers of America</name>
      <address>
        <city>Oakland Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana Research Associates</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana Clinical Research</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanley Street Treatment and Resources</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adams Clinical Trials</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <zip>02472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precise Research Centers, Inc.</name>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Clinical Trials</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altea Research Institute</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hassman Research Institute</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Emotional Fitness</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <zip>08002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Medical Research Network, LLC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuro-behavioral Clinical Research</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Clinical Research Center</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charak Clinical Research Center</name>
      <address>
        <city>Garfield Heights</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Clinical Research Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pahl Pharmaceutical Professionals</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CODA</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tipton Medical and Diagnostic Center aka Clinical Research Associates of Central PA</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPenn Treatment Research Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Clinical Trials</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pillar Clinic Research, LLC</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InSite Clinical Research</name>
      <address>
        <city>DeSoto</city>
        <state>Texas</state>
        <zip>75115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>July 9, 2018</study_first_submitted>
  <study_first_submitted_qc>July 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2018</study_first_posted>
  <last_update_submitted>April 17, 2019</last_update_submitted>
  <last_update_submitted_qc>April 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Opioid recovery</keyword>
  <keyword>Recovery</keyword>
  <keyword>Opioid-related disorders</keyword>
  <keyword>Substance-related disorders</keyword>
  <keyword>Heroin dependence</keyword>
  <keyword>Opioid dependence</keyword>
  <keyword>Addiction</keyword>
  <keyword>Buprenorphine</keyword>
  <keyword>Opiate substitution treatment</keyword>
  <keyword>Analgesics</keyword>
  <keyword>Opioid</keyword>
  <keyword>Narcotics</keyword>
  <keyword>Patient outcome assessment</keyword>
  <keyword>Patient-centered care</keyword>
  <keyword>Cost of illness</keyword>
  <keyword>Employment</keyword>
  <keyword>Health-related quality-of-life</keyword>
  <keyword>Family relations</keyword>
  <keyword>Lifestyle</keyword>
  <keyword>Citizenship</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

